Last updated: October 04, 2026

Application No. 18/750,843

HIGH POTENCY EMULSIONS

Final Rejection

Filed

Jun 21, 2024

Priority

Apr 12, 2021 — provisional 63/173,965 +2 more

Examiner

BORI, IBRAHIM D

Art Unit

1629

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Vertosa Inc.

OA Round

4 (Final)

Interview Optional

— +38.9% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 44% grant rate with +38.9% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 614 resolved cases, 2023–2026

Examiner Intelligence

BORI, IBRAHIM D View full profile →

Grants 44% of resolved cases

Career Allowance Rate

269 granted / 614 resolved

-16.2% vs TC avg

Strong +39% interview lift

Without

With

+38.9%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

40 currently pending

Career history

656

Total Applications

across all art units

Statute-Specific Performance

§101

2.6%

-37.4% vs TC avg

§103

41.4%

+1.4% vs TC avg

§102

15.8%

-24.2% vs TC avg

§112

24.6%

-15.4% vs TC avg

Black line = Tech Center average estimate • Based on career data from 614 resolved cases

Prosecution Timeline

Show 10 earlier events

May 19, 2026

Examiner Interview Summary

May 19, 2026

Applicant Interview (Telephonic)

Jul 17, 2026

Response Filed

Aug 18, 2026

Final Rejection mailed

Aug 19, 2026

Interview Requested

Aug 24, 2026

Interview Requested

Aug 24, 2026

Applicant Interview (Telephonic)

Aug 24, 2026

Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

16/864,955

Patent 12734137

METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE

6y 4m to grant Granted Sep 15, 2026

18/040,102

Patent 12735404

NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF

3y 7m to grant Granted Sep 15, 2026

18/595,808

Patent 12708621

SMALL MOLECULE BAX INHIBITORS AND USES THEREOF

2y 5m to grant Granted Aug 18, 2026

18/560,632

Patent 12692252

COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF

2y 8m to grant Granted Jul 28, 2026

18/291,206

Patent 12686674

CRYSTAL FORM OF COMPOUND REPRESENTED BY FORMULA I, AND PREPARATION THEREFOR AND APPLICATION THEREOF

2y 6m to grant Granted Jul 21, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

44%

Grant Probability

83%

With Interview (+38.9%)

3y 5m (~1y 1m remaining)

Median Time to Grant

High

PTA Risk

Based on 614 resolved cases by this examiner. Grant probability derived from career allowance rate.

HIGH POTENCY EMULSIONS

Interview Optional

Examiner Intelligence

Statute-Specific Performance

Prosecution Timeline

Precedent Cases

Applications granted by this same examiner with similar technology

Strategy Recommendation AI-generated — please review before filing

Prosecution Projections

Ready to respond to this office action?

Sign in with your work email